GlassScriptPhysician profile
Mikki Barker
NPI 1639240740
$5,355.48
in general payments reported to CMS, 2019-2025
17 companies · $765 in 2025
The $765 reported for 2025 was more than what 77% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $515 · 2020: $220 · 2021: $475 · 2022: $291 · 2023: $1,116 · 2024: $1,974 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,828 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,827.74 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,346.44 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $844.13 | 2023-2025 | Invega Trinza, Invega Sustenna, Spravato |
| Alkermes, INC. | $784.54 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $685.29 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $458.92 | 2022-2025 | Caplyta |
| Allergan, INC. | $354.92 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $334.61 | 2019-2025 | Uzedy |
| Otsuka America Pharmaceutical, INC. | $231.86 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Lundbeck LLC | $64.41 | 2024-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $52.56 | 2024 | Cobenfy |
| Sage Therapeutics, LLC | $44.03 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.18 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $37.05 | 2019 | |
| Supernus Pharmaceuticals, INC. | $30.54 | 2022-2025 | Qelbree |
| Shire North American Group INC | $18.70 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $14.75 | 2024 | Loreev Xr |
| Tris Pharma INC | $13.55 | 2024 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mikki Barker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.